Yun Xiao Selected Research

FSC 231

11/2021	FSC231 alleviates paclitaxel-induced neuralgia by inhibiting the interactions between PICK1 and GluA2 and activates GSK-3β and ERK1/2.
10/2021	FSC231 can alleviate paclitaxel-induced neuralgia by inhibiting PICK1 and affecting related factors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yun Xiao Research Topics

Disease

57	Neoplasms (Cancer) 01/2022 - 10/2008
13	Carcinogenesis 01/2021 - 10/2011
10	Breast Neoplasms (Breast Cancer) 01/2022 - 01/2014
6	Glioblastoma (Glioblastoma Multiforme) 12/2019 - 07/2013
5	Hearing Loss (Hearing Impairment) 01/2022 - 01/2016
5	Inflammation (Inflammations) 01/2022 - 01/2013
5	Neoplasm Metastasis (Metastasis) 11/2018 - 02/2015
5	Fibrosis (Cirrhosis) 01/2016 - 10/2006
4	Wounds and Injuries (Trauma) 09/2022 - 10/2016
4	Nasopharyngeal Carcinoma 01/2022 - 01/2019
4	Pain (Aches) 01/2022 - 01/2016
4	Systemic Lupus Erythematosus (Libman-Sacks Disease) 12/2021 - 09/2020
4	Deafness (Deaf Mutism) 01/2021 - 08/2016
4	Lung Neoplasms (Lung Cancer) 01/2021 - 06/2003
3	Multiple Sclerosis 02/2022 - 01/2021
3	Neuroinflammatory Diseases 02/2022 - 07/2020
3	Stroke (Strokes) 01/2022 - 10/2015
3	Ischemic Stroke 01/2022 - 02/2019
3	Triple Negative Breast Neoplasms 01/2022 - 12/2017
3	Malignant Mesothelioma 11/2021 - 01/2017
3	Carcinoma (Carcinomatosis) 01/2020 - 11/2016
3	Adenocarcinoma of Lung 09/2019 - 04/2011
3	Prostatic Neoplasms (Prostate Cancer) 05/2018 - 10/2011
3	Heart Failure 01/2018 - 11/2012
3	Leukemia 01/2017 - 04/2012
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 09/2011 - 10/2008
2	Demyelinating Diseases (Demyelinating Disease) 03/2022 - 01/2022
2	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 03/2022 - 01/2021
2	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2022 - 01/2013
2	Lupus Nephritis 12/2021 - 09/2020
2	Autoimmune Diseases (Autoimmune Disease) 12/2021 - 05/2021
2	Mesothelioma 11/2021 - 01/2017
2	Neuralgia (Stump Neuralgia) 11/2021 - 10/2021
2	Melanoma (Melanoma, Malignant) 04/2021 - 01/2021
2	Renal Cell Carcinoma (Grawitz Tumor) 04/2021 - 12/2017
2	Disease Progression 01/2021 - 01/2018
2	Necrosis 01/2021 - 06/2014
2	Ischemia 07/2020 - 12/2013
2	Retinal Perforations 04/2020 - 01/2018
2	Pulmonary Fibrosis (Fibrosing Alveolitis) 01/2020 - 07/2015
2	Peripheral Nervous System Diseases (PNS Diseases) 01/2020 - 01/2016
2	Ovarian Neoplasms (Ovarian Cancer) 01/2020 - 01/2019
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2020 - 01/2012
2	Mitochondrial Diseases (Mitochondrial Disease) 01/2020 - 01/2018
2	Hypertension (High Blood Pressure) 11/2019 - 01/2016
2	Glioma (Gliomas) 01/2019 - 01/2019
2	Adenocarcinoma 01/2019 - 04/2011
2	Stable Angina 12/2018 - 09/2012
2	Coronary Artery Disease (Coronary Atherosclerosis) 12/2018 - 09/2012

Drug/Important Bio-Agent (IBA)

21	Biomarkers (Surrogate Marker)IBA 11/2021 - 06/2012
16	MicroRNAs (MicroRNA)IBA 01/2021 - 10/2011
16	Long Noncoding RNAIBA 01/2020 - 01/2015
15	Proteins (Proteins, Gene)FDA Link 11/2021 - 04/2011
9	Pharmaceutical PreparationsIBA 04/2022 - 01/2010
9	RNA (Ribonucleic Acid)IBA 01/2022 - 08/2014
9	Biological ProductsIBA 01/2021 - 01/2014
7	Messenger RNA (mRNA)IBA 11/2019 - 10/2011
6	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 04/2002
5	Cisplatin (Platino)FDA LinkGeneric 01/2022 - 05/2013
5	Paclitaxel (Taxol)FDA LinkGeneric 11/2021 - 10/2008
5	Transfer RNA (tRNA)IBA 01/2021 - 01/2016
4	AntibodiesIBA 04/2022 - 05/2014
4	Therapeutic UsesIBA 02/2022 - 07/2015
4	Phosphotransferases (Kinase)IBA 10/2021 - 01/2010
4	Mitochondrial DNA (mtDNA)IBA 11/2020 - 08/2016
4	Competitive Endogenous RNAIBA 09/2020 - 11/2016
3	Interleukin-10 (Interleukin 10)IBA 01/2022 - 07/2020
3	CytokinesIBA 01/2022 - 11/2012
3	Immunoglobulin G (IgG)IBA 12/2021 - 09/2020
3	PlatinumIBA 01/2021 - 01/2019
3	Transforming Growth Factor beta (TGF-beta)IBA 01/2019 - 01/2009
3	AsbestosIBA 10/2017 - 06/2012
3	ErbB Receptors (EGF Receptor)IBA 01/2014 - 10/2008
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 09/2022 - 02/2010
2	Antinuclear AntibodiesIBA 08/2022 - 09/2020
2	Monoclonal AntibodiesIBA 04/2022 - 05/2014
2	CuprizoneIBA 02/2022 - 01/2022
2	Gemcitabine FDA Link 01/2022 - 01/2019
2	Propofol (Diprivan)FDA LinkGeneric 01/2022 - 01/2022
2	montelukast (Singulair)FDA Link 01/2022 - 01/2021
2	Immune Checkpoint InhibitorsIBA 12/2021 - 04/2021
2	Substance PIBA 11/2021 - 10/2021
2	FSC 231IBA 11/2021 - 10/2021
2	Interleukin-6 (Interleukin 6)IBA 01/2021 - 07/2015
2	Circular RNAIBA 01/2021 - 02/2019
2	Small Cytoplasmic RNAIBA 01/2021 - 01/2019
2	Retinaldehyde (Retinal)IBA 04/2020 - 09/2015
2	Sodium Channels (Sodium Channel)IBA 01/2020 - 01/2016
2	ChromatinIBA 01/2020 - 04/2002
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2020 - 09/2019
2	Estrogen ReceptorsIBA 11/2019 - 01/2014
2	LeptinIBA 02/2019 - 01/2014

Therapy/Procedure

26	Therapeutics 04/2022 - 01/2010
8	Drug Therapy (Chemotherapy) 01/2022 - 09/2014
4	Vitrectomy 01/2022 - 01/2018
4	Immunotherapy 01/2022 - 12/2018
2	Induction Chemotherapy 01/2022 - 01/2019
2	Chemoradiotherapy 01/2022 - 01/2019
2	Radiotherapy 11/2021 - 01/2021
2	Sutures (Suture) 01/2020 - 01/2018